With the mission to "supply vaccines to eliminate human diseases", SINOVAC has developed a comprehensive product portfolio vaccinating against traditional endemics such as hepatitis A, seasonal influenza, pneumococcal disease, poliomyelitis, varicella, and mumps; as well as emerging pandemics, such as COVID-19, enterovirus71 (EV71) infected Hand-Foot-Mouth disease (HFMD), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) and SARS.

Based on its comprehensive quality management system, SINOVAC has four vaccines approved by the World Health Organization ("WHO"). Among which, its hepatitis A vaccine Healive^®, Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were granted with WHO prequalification; and its COVID-19 vaccine CoronaVac^® was validated by the WHO under the Emergency Use Listing ("EUL") Procedure.

Up to now, with more than 3 billion doses shipped globally, SINOVAC's vaccines have been used in more than 80 countries and regions, providing protection for a larger number of populations.

The Company is developing several new products including combination vaccines and multivalent vaccines. SINOVAC primarily sells its vaccines in China, while also exploring growth opportunities in international markets.